Comparing trigger point injection with nerve block for chronic migraine
Compares trigger point injection and nerve block in adults with chronic migraine.
Key facts
- Who runs it
- Beijing Tiantan Hospital
- Where
- Beijing, ChinaSee the site
- Trial code
- Registry title
- Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine
- Status
- Recruiting
- People taking part
- 1,036 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 1 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MTrPs Injection
- Greater occipital nerve block group
- Record updated
- 16 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with chronic migraine. They must still have pain despite conservative medicine treatment. They will get an injection at trigger points or at the greater occipital nerve.
- Age
- 18 to 65 years
- Sex
- All sexes can join
- Disease stage
- Migraine diagnosed by at least two pain specialists or neurologists, lasting at least 3 months. Pain score (NRS) of 3 or higher despite conservative medicine treatment.
- Earlier treatment
- Must still have pain (NRS score of 3 or higher) despite conservative treatment with medicines. No long-term steroid treatment.
Main reasons for not taking part
- Allergy to trial medicines such as corticosteroids
- Alcohol abuse or long-term opioid use
- Severe nerve disease, serious liver or kidney problems, heart failure, bleeding or clotting problems, stomach ulcer, diabetes, or inflammatory rheumatic disease
- Infection, local or in the whole body
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Diagnosed with migraine by at least two pain specialists or neurologists
- Disease duration of at least 3 months
- Age between 18 and 65 years
- Numerical Rating Scale (NRS) score ≥ 3 despite conservative pharmacological treatment
- Signed informed consent form
Who cannot take part
- Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy
- History of allergy to trial medications such as corticosteroids
- Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc
- Presence of local or systemic infection
- Inability to use pain assessment scales
- Pregnant or lactating patients
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in China
- Beijing Tiantan HospitalBeijing, ChinaContact: Fang LuoTaking people
About the trial
What the trial wants to find out
Chronic migraine is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with chronic migraine. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and greater occipital nerve block injection in treating chronic migraine. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or greater occipital nerve. After treatment, patients will be followed up for 2 years. Their NRS scores, attack frequency, attack duration, HIT-6 scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for chronic migraine is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.
The 2 groups in the trial
- MTrPs injection groupTreatment being tested
MTrPs injection with triamcinolone acetonide.
Treatment: MTrPs Injection
- Greater occipital nerve block groupExisting treatment, for comparison
Greater occipital nerve block with triamcinolone acetonide.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Musculoskeletal Pain(CMP), Chronic Migraine and Cervicogenic Headache
- Plain-language title
- Comparing trigger point injection with nerve block for chronic migraineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07347067, who can take part
- Record updated
- 16 January 2026